Optimization of Medicinal Treatment of Patients with Glaucoma in Combination with Concurrent System Pathology. Part 1: Cardiovascular Pathology

This paper presents clinical and pharmacological drug interactions for the treatment of patients with glaucoma combined with concurrent cardiovascular pathology, risks of side effects, and adverse drug reactions. The article discusses the multifactor nature of glaucoma, age factors, and the direction of local and systemic pathogenetic treatment, principles of the personified approach, and its feasibility. It is shown that an essential element of this approach can be a system of questionnaires for glaucoma patients with chronic diseases, the principal place in which is occupied by a questionnaire filled out by the patient himself. Digital processing of individual data and assessments provided by patients allows us to implement the tasks of a personalized approach to the treatment. Analysis of the pharmacological effects of the available and used arsenal of medicinal products allows you to generalize the array of data obtained, to form model algorithms for deciding by an ophthalmologist on the choice of medications. In scheme optimizing of the prescribed medications, it is important to cross-inform between specialists of different profiles (ophthalmologists, therapists, neurologists, cardiologists, endocrinologists, rheumatologists, etc.), create an algorithm for entering the medications of choice and their rational combinations, which reduces the risk of polypragmasia. Possible causes of progression of glaucoma optic neuropathy (GON) against the background of age-related systemic diseases (using the example of the cardiovascular system’s pathology) are considered. Ways of influencing the pathogenetic links of the glaucomatous process are proposed from the standpoint of an optimal combination of medications. Analysis of literature on the problem of structural and functional disorders in GON’s development shows that it is promising to expand our understanding of the fundamental processes underlying these changes, search for clinically significant combinations of contemporary markers of changes in structure and function, and, accordingly, treatment approaches. The possibilities of neuroprotection of glaucoma optical neuropathy, as well as modern methods of electrophysiological research in the monitoring assessment of its effectiveness and the differential diagnosis, approaches to enhance the effectiveness of medications treatment with combined medications are analyzed in the article.

primary open-angle glaucoma, cardiovascular diseases, neuroprotection, polypragmasia, drug interaction, pathogenetic therapy

1. Оnishchenko A.l., Kolbasko A.V., Zakharova A.V., Onishchenko E.G., Zhilina N.M. Ophthalmic hypotensive effect of the beta-blockers systemic use in primary glaucoma and arterial hypertension. Annals of Ophthalmology = Vestnik oftal’mologii. 2017;133(2):46–51 (In Russ.). DOI: 10.17116/oftalma2017133246-50

2. Stein J.D., Newman-Casey P.N., Niziol L.M., Gillespie B.W., Lichter P.R., Musch D.C. Association between the use of glaucoma medications and mortality. Arch Ophthalmol. 2010;128(2):235–240. DOI: 10.1001/archophthalmol.2009.378

3. De Moraes C.G., Cioffi G.A., Weinreb R.N., Liebmann J.M. New Recommendations for the Treatment of Systemic Hypertension and their Potential Implications for Glaucoma Management. Journal of Glaucoma. 2018;27(7):567–571. DOI: 10.1097/IJG.0000000000000981

4. Pereira K.G., Peres M.A., Iop D., Boing A.C., Boing A.F., Aziz M., d’Orsi E. Polypharmacy among the elderly: a population-based study. Rev. Bras. Epidemiol. 2017;20(2):335–344. DOI: 10.1590/1980-5497201700020013

5. Macdonald M.J., Cullen P.M., Phillips C.I. Atenolol versus propranolol. A comparison of ocular hypotensive effect of an oral dose. Br. J Ophthalmol. 1976;60(11):789– 791. DOI: 10.1136/bjo.60.11.789

6. Szumny D., Szeląg A. The influence of new beta-adrenolytics nebivolol and carvedilol on intraocular pressure and iris blood flow in rabbits. Graefes Arch. Clin. Exp. Ophthalmol. 2014;252(6):917–923. DOI: 10.1007/s00417-014-2623-5

7. Khawaja A.P., Chan M.P.Y., Broadway D.C., Garway-Heath D.F., Luben R., Yip D.L.Y., Hayat S., Wareham N.J., Khaw K., Foster P.J. Systemic medication and intraocular pressure in a British population: The EPIC-Norfolk Eye Study Ophthalmology. 2014;121(8):1501–1507. DOI: 10.1016/j.ophtha.2014.02.009

8. Sychjov D.A., Moshetova L.K. Clinical and pharmacological aspects of combined pathology: cardiovascular diseases and glaucoma. National Journal Glaucoma = Natsional’nyi zhurnal glaucoma. 2014;13(2):99–104 (In Russ.).

9. Lama P.J. Systemic adverse effects of beta-adrenergic blockers: an evidencebased assessment. Am. J Ophthalmol. 2002;134(5):749–760. DOI: 10.1016/s00029394(02)01699-9

10. Zimmerman T.J., Kooner K.S., Kandarakis A.S., Ziegler L.P. Improving the therapeutic index of topically applied ocular drags. Arch. Ophthalmol. 1984;102(7):601– 604. DOI: 10.1001/archopht.1984.01040030429017

11. Williamson J., Young J.D., Atta H., Muir J., Kadom H. Comparative efficacy of orally and topically administered beta-blockers for chronic simple glaucoma. Br. J Ophthalmol. 1985;69(1):41–45. DOI: 10.1136/bjo.69.1.41

12. Saxena R., Prakash J., Gupta S. Pharmacotherapy of glaucoma. Indian Journal of Pharmacology. 2002;34:71–85

13. Hoste A.M. Beta-Blockers in “Glaucoma. Medical Diagnosis & Therapy” / Shaarawy T.M., Sherwood M.B., Hitchings R.A., Crowston J.G., eds. Elsevier, London. 2014:548–558.

14. Kukes V.G., Grachev S.V., Ramenskaya G.B. Metabolism of medications: scientific principles of personalized medicine. Moscow: GEOTARMedia, 2008:304 (In Russ.).

15. Diggory P., Franks W. Medical treatment of glaucoma — a reappraisal of the risks. Br. J Ophthalmol. 1996;80(1):85–89. DOI: 10.1136/bjo.80.1.85

16. Grunwald J.E., DuPont J., Dreyer E.B. Effect of chronic nitrate treatment on retinal vessel caliber in open-angle glaucoma. Am. J. Ophthalmol. 1997;123(6):753–758. DOI: 10.1016/s0002-9394(14)71123-7

17. Wizemann A.J., Wizemann V. Organic nitrate therapy in glaucoma. Am. J Ophthalmol. 1980;90(1):106–109. DOI: 10.1016/s0002-9394(14)75085-8

18. Neroev V.V., Kiseleva O.A., Bessmertnyj A.M. The main results of a multicenter study of the epidemiological features of primary open-angle glaucoma in the Russian Federation. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2013;6(3):4–7 (In Russ.).

19. Caughey G.E., Rouhead E.E., Shakib S., Vitry A.I., Gilbert A.L. Co-morbidity and potential treatment conflicts in elderly heart failure patients: a retrospective, crosssectional study of administrative claims data. Drugs Aging. 2011;28(7):575–581. DOI: 10.2165/11591090000000000-00000

20. Gandolfi S.A., Lim J., Sanseau A.C., Restrepo J., Hamacher T. Randomized trial of Brinzolamide/Brimonidine versus Brinzolamide plus Brimonidine for open-angle glaucoma or ocular hypertension. Adv Ther. 2014;31(12):1213–1277. DOI: 10.1007/s12325-014-0168

21. Aung T., Laganovska G., Hernandez Paredes T.J., Branch J.D., Tsorbatzoglou A., Goldberg I. Twice-Daily Brinzolamide/Brimonidine Fixed Combination versus Brinzolamide or Brimonidine in Open-Angle Glaucoma or Ocular Hypertension. Original article. Ophthalmology 2014;121(12):2348–2355. DOI: 10.1016/j.ophtha.2014.06.022

22. Onder G., Petrovic M., Tangiisuran B., Meinardi M., Markito-Notenboom W., Somers A., Rajkumar C., Bernabei R., van der Cammen T. Development and Validation of a Score to Assess Risk of Adverse Drug Reactions Among In-Hospital Patients 65 Years or Older. Arch Int Med. 2010;170(13):1142–1148. DOI: 10.1001/archinternmed.2010.153

23. Zhuravleva A.N., Kiseleva O.A., Kirillova M.O. Personalized medicine in glaucoma menegement. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2019;12(3):95–100 (In Russ.). DOI:10.21516/2072-0076-2019-12-3-95-100

24. Neroev V.V., Zueva M.V., Zhuravleva A.N., Tsapenko I.V. Structural and functional disorders in glaucoma: the prospects for preclinical diagnosis. Part 1. How relevant is the search for what comes first? Ophthalmology in Russia. 2020;17(3):336–343 (In Russ.).

25. Zhuravleva A.N., Zueva M.V. Hypotensive glaucoma therapy and neuroprotection. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2020;13(2):78– 82 (In Russ.). DOI: 10.21516/2072-0076-2020-13-2-78-82

26. Sychev D.A., Otdelеnov V.A., Krasnova N.M., Ilyina E.S. Polypragmasy: a clinical pharmacologist’s view. Therapeutic Archive = Terapevticheskiy arkhiv. 2016;88(12):94–102. (In Russ.). DOI: 10.17116/terarkh2016881294-102

27. Flammer J., Konieczka K., Bruno R.M., Virdis A., Flammer A.J., Taddei S. The eye and the heart. Eur Heart J. 2013;34(17):1270–1278. DOI: 10.1093/eurheartj/eht023

28. Zueva M.V. The aging of the retina. Part II. Adaptive processes and plasticity. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2010;3(3):54–62 (In Russ.).

29. Burke S.N., Barnes C.A. Neural plasticity in the ageing brain. Nat. Rev. Neurosci. 2006;7:30–40. DOI: 10.1038/nrn1809

30. Owsley C., Jackson G.R., Cideciyan A.V., Huang Y., Fine S.L., Ho A.C., Maguire M.G., Lolley V., Jacobson S.G. Psychophysical Evidence for Rod Vulnerability in Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2000;41:267–273. http://www.iovs.org/content/41/1/267.full.pdf

31. Gerth C. The role of the ERG in the diagnosis and treatment of age-related macular degeneration. Doc. Ophthalmol. 2009;118:63–68. DOI: 10.1007/s10633-008-9133-x

32. Birch D.G., Anderson J.L. Standardized full-field electroretinography. Normal values and their variation with age. Arch. Ophthalmol. 1992;110:1571–1576. DOI: 10.1001/archopht.1992.01080230071024

33. Jackson G.R., Ortega J., Girkin C., Rosenstiel C.E., Owsley C. Aging-related changes in the multifocal electroretinogram. J. Opt. Soc. Amer. A. Opt. Image Sci. Vis. 2002;19:185–189. DOI : 10.1364/josaa.19.000185

34. Jackson G.R., Mc Gwin G., Jr. Phillips J.M., Klein R., Owsley C. Impact of aging and age-related maculopathy on activation of the a-wave of the rod-mediated electroretinogram. Invest. Ophthalmol. Vis. Sci. 2004;45:3271–3278. DOI: 10.1167/iovs.040019

35. Gerth C., Garcia S.M., Ma L., Keltner J.L., Werner J.S. Multifocal electroretinogram: age-related changes for different luminance levels. Graefe’s Arch. Clin. Exp. Ophthalmol. 2002;240:202–208. DOI: 10.1007/s00417-002-0442-6

36. Banitt M.R., Ventura L.M., Feuer W.J., Savatovsky E., Luna G., Shif O., Bosse B., Porciatti V. Progressive loss of retinal ganglion cell function precedes structural loss by several years in glaucoma suspects. Invest. Ophthalmol. Vis. Sci. 2013;54:2346–2352. DOI : 10.1167/iovs.12-11026

37. Feng L., Zhao Y., Yoshida M., Chen H., Yang J.F., Kim T.S., Cang J., Troy J.B., Liu X. Sustained ocular hypertension induces dendritic degeneration of mouse retinal ganglion cells that depends on cell type and location. Invest. Ophthalmol. Vis. Sci. 2013;54:1106–1117. DOI : 10.1167/iovs.12-10791

38. Zueva M.V. Dynamics of retinal ganglion cell death in glaucoma and its functional markers. National Journal glaucoma = Natsional’nyi zhurnal glaukoma. 2016;15(1):70–85 (In Russ.)

39. Stjernschantz J., Selen G., Astin M., Resul B. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment. Prog. Retin. Eye Res. 2000;19:459–496. DOI: 10.1016/s13509462(00)00003-3

40. Lambert W.S., Ruiz L., Crish S.D., Wheeler L.A., Calkins D.J. Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons. Mol. Neurodegener. 2011;6(4). DOI : 10.1186/1750-1326-6-4.